Published in Cell on November 11, 2011
Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer (2013) 6.13
The Hippo pathway and human cancer. Nat Rev Cancer (2013) 5.17
The Hippo pathway: regulators and regulations. Genes Dev (2013) 4.55
Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol (2012) 3.07
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov (2013) 3.03
The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell (2012) 2.84
The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer (2015) 2.74
Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol (2013) 2.58
The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A (2012) 2.51
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell (2015) 2.31
LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med (2012) 2.24
The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol (2012) 2.21
Soft fibrin gels promote selection and growth of tumorigenic cells. Nat Mater (2012) 2.15
Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell (2013) 2.08
Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev (2012) 1.86
The evolving concept of cancer and metastasis stem cells. J Cell Biol (2012) 1.76
The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep (2014) 1.73
Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J Cell Sci (2013) 1.63
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology (2013) 1.58
Metabolic profiling reveals PAFAH1B3 as a critical driver of breast cancer pathogenicity. Chem Biol (2014) 1.55
TAZ expression as a prognostic indicator in colorectal cancer. PLoS One (2013) 1.55
Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. Curr Opin Cell Biol (2014) 1.55
Organ size control by Hippo and TOR pathways. Curr Biol (2012) 1.45
TIAM1 Antagonizes TAZ/YAP Both in the Destruction Complex in the Cytoplasm and in the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells. Cancer Cell (2017) 1.41
A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat Cell Biol (2013) 1.41
Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol (2015) 1.39
Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity. Proc Natl Acad Sci U S A (2013) 1.38
YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle (2012) 1.34
Function and cancer genomics of FAT family genes (review). Int J Oncol (2012) 1.34
Disease implications of the Hippo/YAP pathway. Trends Mol Med (2015) 1.32
The metastatic niche and stromal progression. Cancer Metastasis Rev (2012) 1.30
A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev (2014) 1.30
Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J (2014) 1.30
YAP and TAZ: a nexus for Hippo signaling and beyond. Trends Cell Biol (2015) 1.29
Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Metab (2012) 1.28
Growth control by committee: intercellular junctions, cell polarity, and the cytoskeleton regulate Hippo signaling. Dev Cell (2012) 1.26
The hypoxic tumor microenvironment: A driving force for breast cancer progression. Biochim Biophys Acta (2015) 1.25
The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep (2014) 1.24
Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res (2014) 1.18
The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFβ-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition. J Biol Chem (2012) 1.17
The transcriptional regulators TAZ and YAP direct transforming growth factor β-induced tumorigenic phenotypes in breast cancer cells. J Biol Chem (2014) 1.17
Signal integration in TGF-β, WNT, and Hippo pathways. F1000Prime Rep (2013) 1.15
TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle (2012) 1.15
Defining the protein-protein interaction network of the human hippo pathway. Mol Cell Proteomics (2013) 1.14
Cell shape and the microenvironment regulate nuclear translocation of NF-κB in breast epithelial and tumor cells. Mol Syst Biol (2015) 1.11
Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J (2015) 1.11
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat Commun (2015) 1.10
Interaction proteome of human Hippo signaling: modular control of the co-activator YAP1. Mol Syst Biol (2013) 1.10
Regulation and functions of mammalian LATS/NDR kinases: looking beyond canonical Hippo signalling. Cell Biosci (2013) 1.09
Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells. Nat Commun (2015) 1.09
Regulation of the Hippo pathway and implications for anticancer drug development. Trends Pharmacol Sci (2013) 1.07
Emerging roles of claudins in human cancer. Int J Mol Sci (2013) 1.05
ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer. Proc Natl Acad Sci U S A (2012) 1.04
The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl. Cell Death Differ (2013) 1.04
Molecular characterisation of cell line models for triple-negative breast cancers. BMC Genomics (2012) 1.03
Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget (2014) 1.03
Cancer cells incorporate and remodel exogenous palmitate into structural and oncogenic signaling lipids. Biochim Biophys Acta (2013) 1.02
A basal-like breast cancer-specific role for SRF-IL6 in YAP-induced cancer stemness. Nat Commun (2015) 1.02
The role of the Hippo pathway in human disease and tumorigenesis. Clin Transl Med (2014) 0.99
Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration. Sci Signal (2014) 0.98
Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov (2016) 0.98
A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma. Mol Cancer Res (2015) 0.97
Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol (Dordr) (2013) 0.96
Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J Exp Med (2014) 0.96
The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Oncotarget (2014) 0.95
MicroRNA-141 inhibits tumor growth and metastasis in gastric cancer by directly targeting transcriptional co-activator with PDZ-binding motif, TAZ. Cell Death Dis (2015) 0.94
Emerging roles of the tumor-associated stroma in promoting tumor metastasis. Cell Adh Migr (2012) 0.94
Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol Med (2013) 0.94
Control of organ growth by patterning and hippo signaling in Drosophila. Cold Spring Harb Perspect Biol (2015) 0.92
"You Shall Not Pass"-tight junctions of the blood brain barrier. Front Neurosci (2014) 0.92
Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. FEBS Open Bio (2015) 0.92
Regulation of lung cancer metastasis by Klf4-Numb-like signaling. Cancer Res (2013) 0.91
Integration of mechanical and chemical signals by YAP and TAZ transcription coactivators. Cell Biosci (2013) 0.91
Estrogen regulates Hippo signaling via GPER in breast cancer. J Clin Invest (2015) 0.91
TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma. Cancer Sci (2015) 0.91
The hippo pathway in heart development, regeneration, and diseases. Circ Res (2015) 0.91
ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence. Cell Death Differ (2013) 0.91
A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells. Genes Dev (2015) 0.90
Notch is a direct negative regulator of the DNA-damage response. Nat Struct Mol Biol (2015) 0.90
Human tumour viruses and the deregulation of cell polarity in cancer. Nat Rev Cancer (2012) 0.90
Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor. Clin Cancer Res (2015) 0.90
Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Sci Rep (2013) 0.90
YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells. PLoS One (2014) 0.90
Transcriptional co-activator TAZ sustains proliferation and tumorigenicity of neuroblastoma by targeting CTGF and PDGF-β. Oncotarget (2015) 0.90
Hypoxia-inducible factors in cancer stem cells and inflammation. Trends Pharmacol Sci (2015) 0.90
ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat Commun (2016) 0.90
Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. EMBO J (2015) 0.89
Differential regulation of the Hippo pathway by adherens junctions and apical-basal cell polarity modules. Proc Natl Acad Sci U S A (2015) 0.89
YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes. Oncotarget (2014) 0.89
Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol (2016) 0.89
Adhesion glycoprotein CD44 functions as an upstream regulator of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression. Oncotarget (2015) 0.89
A microRNA code for prostate cancer metastasis. Oncogene (2015) 0.89
A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. Cell Res (2015) 0.89
Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib. Cell Biosci (2015) 0.89
Early effects of the antineoplastic agent salinomycin on mitochondrial function. Cell Death Dis (2015) 0.88
The Yes-associated protein controls the cell density regulation of Hedgehog signaling. Oncogenesis (2014) 0.88
The Spectrin cytoskeleton regulates the Hippo signalling pathway. EMBO J (2015) 0.87
Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway. Mol Cancer Res (2015) 0.87
The Hippo pathway in disease and therapy: cancer and beyond. Clin Transl Med (2014) 0.87
The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway. Oncotarget (2014) 0.87
Role of YAP/TAZ in mechanotransduction. Nature (2011) 11.56
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci U S A (2003) 7.60
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
MicroRNA control of signal transduction. Nat Rev Mol Cell Biol (2010) 5.74
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
A MicroRNA targeting dicer for metastasis control. Cell (2010) 4.81
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell (2009) 4.11
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol (2010) 4.09
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med (2007) 4.04
Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2008) 3.98
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69
Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell (2003) 3.45
Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst (2005) 3.26
Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res (2007) 3.19
A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell (2013) 3.17
Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci (2004) 3.12
Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol (2012) 3.07
Role of TAZ as mediator of Wnt signaling. Cell (2012) 3.05
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood (2012) 3.02
Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell (2006) 2.84
Methods for interpreting lists of affected genes obtained in a DNA microarray experiment. BMC Proc (2009) 2.80
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol (2011) 2.76
Wnt/beta-catenin signaling acts upstream of N-myc, BMP4, and FGF signaling to regulate proximal-distal patterning in the lung. Dev Biol (2005) 2.73
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med (2013) 2.67
Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell (2005) 2.66
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med (2011) 2.59
Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol (2004) 2.57
The Atx1-Ccc2 complex is a metal-mediated protein-protein interaction. Nat Chem Biol (2006) 2.56
miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res (2009) 2.52
CASD-NMR: critical assessment of automated structure determination by NMR. Nat Methods (2009) 2.50
SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature (2012) 2.46
Counting the zinc-proteins encoded in the human genome. J Proteome Res (2006) 2.38
Novel definition files for human GeneChips based on GeneAnnot. BMC Bioinformatics (2007) 2.32
Wnt/beta-catenin signaling directs multiple stages of tooth morphogenesis. Dev Biol (2007) 2.26
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood (2004) 2.19
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood (2011) 2.18
Reciprocal requirements for EDA/EDAR/NF-kappaB and Wnt/beta-catenin signaling pathways in hair follicle induction. Dev Cell (2009) 2.17
Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol (2010) 2.14
Zinc through the three domains of life. J Proteome Res (2006) 2.11
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol (2005) 2.10
Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat Med (2010) 2.10
MicroRNA control of Nodal signalling. Nature (2007) 2.09
Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood (2009) 2.08
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res (2004) 1.99
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ (2005) 1.97
Activation of beta-catenin signaling programs embryonic epidermis to hair follicle fate. Development (2008) 1.96
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
Argininosuccinate lyase deficiency: mutational spectrum in Italian patients and identification of a novel ASL pseudogene. Hum Mutat (2007) 1.91
Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood (2013) 1.87
Toll-like receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system. Gastroenterology (2013) 1.83
WT1 mutations in T-ALL. Blood (2009) 1.75
Rational design of shepherdin, a novel anticancer agent. Cancer Cell (2005) 1.74
Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol (2011) 1.71
Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell (2008) 1.70
BMP signaling controls muscle mass. Nat Genet (2013) 1.68